|
Aug 14
|
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 14
|
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
|
|
Aug 11
|
RenovoRx, Inc.'s (NASDAQ:RNXT) Shift From Loss To Profit
|
|
Aug 6
|
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
|
|
Jul 28
|
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
|
|
Jul 14
|
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
|
|
Jul 1
|
Will RenovoRx (NASDAQ:RNXT) Spend Its Cash Wisely?
|
|
May 1
|
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
|
|
Apr 29
|
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
|
|
Feb 13
|
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
|
|
Feb 11
|
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
|
|
Dec 30
|
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
|
|
Sep 26
|
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
|
|
Jun 26
|
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
|
|
Apr 16
|
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
|
|
Apr 15
|
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
|
|
Feb 6
|
RenovoRx CEO Issues Letter to Shareholders
|
|
Jan 29
|
RenovoRx Closes $6.1 Million Private Placement
|
|
Dec 21
|
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
|
|
Dec 19
|
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
|